Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So much for their science.
They sold all and moved on.....
Last I heard, TPIV rejected by Nasdaq. No uplist.
JACKSONVILLE, Florida, April 7, 2016 /PRNewswire/ --
Doses for use at Mayo Clinic and other clinical sites
Stable, easily reconstituted product contains five folate receptor alpha peptides in a single vial
TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today it has successfully completed formulation development, scale-up, GMP (Good Manufacturing Practice) manufacturing, and the release of TPIV 200, its multi-epitope folate receptor peptide vaccine for breast and ovarian cancer. The manufactured product contains five peptide antigens freeze dried in a single vial, ready for injection after reconstitution and addition of granulocyte-macrophage colony-stimulating factor (GM-CSF). TPIV 200 doses are now available for the upcoming Phase II clinical trials in both triple negative breast cancer and ovarian cancer.
http://finance.yahoo.com/news/tapimmune-completes-gmp-manufacturing-release-123000699.html
Maybe you should ask Rogerthat1 so he/she could type up another email for you.
Rogerthat1 Monday, 02/15/16 10:51:16 AM
Re: Rogerthat1 post# 13093
Post #
13104
of 14471 Go
Based on response below from Glynn - it appears IMO that partnership with BP is basically a GO. Why else would they push back their large PII in TNBC with Mayo for Q2 unless they're going to undertake something else of same or greater magnitude? Ie PII trial with BP in Ovarian with inhibitor IMO.
Quote:
Thanks for your support. We expect two Phase II trials to start this quarter – our own Phase II in Triple Negative Breast Cancer and our Phase II in ovarian cancer in combination with a checkpoint inhibitor and a pharma partner. The large Phase II trial in Triple Negative at the Mayo Clinic (and funded by the Department of Defense) will start Q2. As you indicated we had hoped to announce the combination study with the Pharma partner earlier but administrative details and agreements in a three-way collaboration (TPIV-Cancer Institute-Pharma partner) can often take longer than expected. I will announce this as soon as I can with the trial scheduled to start this Q. Despite this we are excited by our progress and the plans for this year.
Best regards
Glynn
Glynn Wilson, Ph.D.
Chairman & CEO
TapImmune Inc.
50 North Laura Street, Suite 2500
Jacksonville, FL 32202
904.516.5436
You typed this up yourself?
TPIV
ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934
TapImmune Inc. submitted an application under Rule 24b-2 requesting
confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed
on August 14, 2015.
Based on representations by TapImmune Inc. that this information qualifies as
confidential commercial or financial information under the Freedom of Information Act,
5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly
disclose it. Accordingly, excluded information from the following exhibit will not be
released to the public for the time period specified:
Exhibit 10.1 through July 21, 2020
For the Commission, by the Division of Corporation Finance, pursuant to
delegated authority:
Brent J. Field
http://quotemedia.10kwizard.com/cgi/convert/pdf/TPIV-20160204-CTORDER-0.pdf?pdf=1&repo=tenk&ipage=10711782&num=-2&pdf=1&xml=1&dn=2&quest=1&rid=23&dn=3
TPIV
TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
http://finance.yahoo.com/news/tapimmune-granted-fast-track-designation-133000251.html
JACKSONVILLE, Florida, February 3, 2016 /PRNewswire/ --
Expedites TapImmune's clinical development program for ovarian cancer
Follows recent Orphan Drug Designation for TPIV 200 in the same indication
TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for its cancer vaccine TPIV 200 in the treatment of ovarian cancer.
The FDA has designated the investigation of multiple-epitope Folate Receptor Alpha Peptide Vaccine (TPIV 200) with GM-CSF adjuvant for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer who achieved stable disease or partial response following completion of standard of care chemotherapy, as a Fast Track Development Program.
Under the FDA Modernization Act of 1997, designation as a Fast Track product for a new drug or biological product means that the FDA will take such actions as are appropriate to expedite the development and review of the application for approval of such product.
"We believe that the FDA's decision to grant Fast Track designation to TPIV 200 for the treatment ovarian cancer significantly expedites our clinical development program. We look forward to starting Phase II trials in the near future to address this highly aggressive cancer", commented Dr. Glynn Wilson Chairman & CEO of TapImmune. "We believe that TPIV 200 has the potential to improve outcomes for ovarian cancer patients for whom current treatment modalities offer a relative short time to recurrence and a poor overall prognosis".
Approximately 21,290 women were diagnosed with ovarian cancer in 2015 and an estimated 14,180 will die from the disease according to the American Cancer Society. Because ovarian cancer tends to be detected at a later stage of the disease, the five-year survival rate for ovarian cancer is 45%. Current treatment options are surgery, radiation and chemotherapy. There is currently no FDA approved cancer vaccine available for ovarian cancer.
Hi Matt,
You still in this one? What do you think of the price action?
Thanks
MELBOURNE, Fla., Feb. 1, 2016 /PRNewswire/ -- Wocket® smart wallet (www.wocketwallet.com) announces the launch of a new video featuring singer, dancer, actor and television personality, Joey Fatone.
http://finance.yahoo.com/news/wocket-smart-wallet-launches-social-130000246.html
I think tomorrow will be a good day for me to exit TPIV.
I don't think there's such a thing as partnership.
On the New York Stock Exchange (NYSE), one type of trading curb is referred to as a "circuit breaker." These limits were put in place after Black Monday in order to reduce market volatility and massive panic sell-offs, giving traders time to reconsider their transactions.
At the start of each quarter, the NYSE sets three circuit breaker levels at levels of 7% (Level 1), 13% (Level 2), and 20% (Level 3) of the average closing price of the S&P 500 for the month preceding the start of the quarter, rounded to the nearest 50-point interval. As of the first quarter of 2014, these levels are 126 points, 234 points, and 360 points respectively.[2] Depending on the point drop that happens and the time of day when it happens, different actions occur automatically: Level 1 and Level 2 declines result in a 15-minute trading halt unless they occur after 3:25pm, when no trading halts apply. A Level 3 decline results in trading being suspended for the remainder of the day.
Trading curbs on Dow futures contracts traded on the Chicago Board of Trade are based on NYSE levels, with the exception that only the 10% threshold is in effect outside of regular NYSE trading hours, and is relative to the previous daily settlement price.
Totally agree! And the warrants as well.
He sold half I'm sure.
My avg is .69. Will see.....
Your thought on the PR of this partnership? Why isn't out yet?
I have a boatload. Thinking about adding more but will watch and wait.
From SHEFF's board:
$heff Member Level Friday, 12/11/15 03:32:33 PM
Re: $heff post# 91967
Post #
91969
of 92024 Go
$TPIV..$.69..The question is not if the partnership has occurred but when it can be announced & with who. CEO already said its a done deal & put it in his company presentation last week. The protocol & partner have been approved in Ovarian Cancer.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119107735
I'm wondering why TPIV have not PR this partnership deal. Anybody?
Same here.... and thanks for the info!
This is approved? FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
JACKSONVILLE, Florida, November 30, 2015 /PRNewswire/ --
TapImmune, Inc. (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at the 8th Annual LD Micro Main Event on December 1, 2015 at 2.30 PM PT. Dr. John N. Bonfiglio a TapImmune Board member and Strategic Advisor will be giving the presentation and will join TapImmune management in meeting with investors.
The conference will be held at the Luxe Sunset Bel Air Hotel, Los Angeles, CA, and will feature 210 companies in the small/micro-cap space. To view a webcast of the presentation please visit:
http://wsw.com/webcast/ldmicro9/tpiv
http://finance.yahoo.com/news/tapimmune-present-ld-micro-main-133000971.html
I'm guessing San Antonio Breast Cancer Symposium
https://www.sabcs.org/
Could you post/share it on here?
Recap offers are oversubscribed
Sources say that National has received bids for 1 billion euros, also exceeding the target it had set for covering the needs of the baseline scenario of the stress tests. The details are also expected on Thursday, with the transaction to be completed in the coming days.
Next week National will also run a public offering for Greek investors who will be able to enter the process on the same terms as their international counterparts for an initial amount of up to 146 million euros.
http://www.ekathimerini.com/203569/article/ekathimerini/business/recap-offers-are-oversubscribed
Some of us already have access to this info!
The truth is you have no clues as to when NBG will close their book and date of RS, do you? LOL.
Greece struck a deal with European creditors Tuesday on economic measures it needs to make to get its next batch of bailout money, including a 10-billion-euro ($10.7 billion) cash injection for its crippled banks.
http://www.ekathimerini.com/203503/article/ekathimerini/business/greece-creditors-strike-substantive-agreement
Greece finance minister says deal reached with lenders for aid disbursement
An agreement has been reached with Greece's lenders on financial reforms which will release a new tranche of aid to the country, Finance Minister Euclid Tsakalotos said early on Tuesday.
"There was an agreement on all the milestones ... whatever was required," Tsakalotos told reporters after meeting representatives of European institutions and the International Monetary Fund on aid disbursement.
Greece had signed up to a new aid program worth up to 86 billion euros earlier this year, but payment of part of an initial tranche had been held up over disagreement on regulations on home foreclosures and handling tax arrears to the state.
Tsakalotos said the deal meant Greece's parliament could now ratify the deal to law, and that deputy euro finance ministers would on Friday affirm the deal. That would allow a two billion euro aid disbursement and 10 billion in recapitalization aid to the country's four main banks.
http://www.reuters.com/article/2015/11/16/us-eurozone-greece-minister-idUSKCN0T52S920151116
Greece and its eurozone creditors have reached an agreement on many issues in the reform programme that Athens is implementing in return for loans, the head of euro zone finance ministers Jeroen Dijsselbloem said in a statement on Sunday.
Greece needs a positive review of its reform progress from the euro zone to get the next, 2 billion euro tranche of loans as well as up to 10 billion euros for the recapitalisation of its banks.
But talks, which should have been completed by the middle of October, have stalled because of differences over details of a foreclosures law.
"I welcome that good progress has been made between the Greek authorities and the institutions in the discussions on the measures included in the first set of milestones and on the financial sector measures that are essential for a successful recapitalisation process," Dijsselbloem said.
"Agreement has been reached on many issues," he said.
He said deputy euro zone finance ministers, called the Euro Working Group (EWG) would meet on Tuesday to take stock of the situation and decide if a disbursement is possible.
http://www.ekathimerini.com/203435/article/ekathimerini/business/greece-and-lenders-have-reached-agreement-on-many-issues-says-dijsselbloem
World Bank's IFC to pump up to 300 mln euros in Greek banks' recap
http://www.ekathimerini.com/203382/article/ekathimerini/business/world-banks-ifc-to-pump-up-to-300-mln-euros-in-greek-banks-recap
EBRD to buy up to 250 mln euros of Greek bank stakes, source says
http://www.ekathimerini.com/203379/article/ekathimerini/news/ebrd-to-buy-up-to-250-mln-euros-of-greek-bank-stakes-source-says
Their conference/meeting (video).
Here you go:
The pressure is on following Monday’s Eurogroup, where officials urged Greece to adopt all the prior actions in an initial list drawn up by lenders along with more reforms on bank governance by the beginning of next week. In exchange, creditors will unlock a 2-billion-euro loan tranche and release 10 billion euros set aside for the recapitalization of Greek banks. A session of the Euro Working Group scheduled for Monday is to assess whether Greece has met the conditions for funding to be released.
http://www.ekathimerini.com/203334/article/ekathimerini/news/government-to-roll-pending-measures-into-new-multi-bill
http://www.mondovisione.com/media-and-resources/news/esma-approves-greek-hcmc-short-selling-ban-on-bank-shares-1/
ESMA Approves Greek HCMC Short Selling Ban On Bank Shares
Date 09/11/2015
The European Securities and Markets Authority (ESMA) has issued its opinion agreeing to an emergency short selling prohibition by the Hellenic Capital Market Commission (HCMC) under the Short Selling Regulation which replaces the prohibition that is expiring at 24:00:00 (CET) on Monday 9 November 2015.
The measure will remain in place until 24:00:00 (CET) on 7 December 2015 and temporarily prohibits transactions in any shares of five credit institutions admitted to trading on the Athens Exchange and the Multilateral Trading Facility of “EN.A” (Alternative Market of the Athens Exchange). It will also concern all depository receipts (ADRs, GDRs) representing those shares . This ban includes sales which are covered with subsequent intraday purchases.
The short selling measure applies to any natural or legal person, irrespective of their country of residence, but would be subject to the exemption for market making activities, provided that short selling transactions are conducted for hedging purposes.
ESMA considers that adverse developments which constitute a serious threat to market confidence in the Greek market still persist and that the proposed measure is appropriate and proportionate to address those threats.